Abbott Laboratories

$19.00

Want a discount? Become a member by purchasing Annual Subscription!
SKU: ABT Category:

Description

Abbott Laboratories managed to exceed analyst expectations in terms of revenue as well as earnings, boasting an adjusted earnings per share of $1.14. The noteworthy achievement of double-digit organic sales growth in all major businesses for the third consecutive quarter, excluding COVID testing, underscored Abbott’s robust market position in high-growth sectors. The acceleration in sales growth is attributed to strategic positioning in attractive markets, fortified by additional investments made during the pandemic. With a positive growth outlook and momentum permeating its diverse portfolio, its team anticipates a robust conclusion to the year and a promising trajectory into 2024. In Nutrition, Pediatric Nutrition witnessed a remarkable 25% growth, securing leadership in the US infant formula market. Adult Nutrition experienced a 12% surge driven by strong demand for Ensure and Glucerna brands. Established Pharmaceuticals achieved an 11% sales increase, marked by double-digit growth in various therapeutic areas. Diagnostics, excluding COVID testing, showcased a 10% organic sales growth driven by Core Lab Diagnostics and a rebound in blood transfusion testing. Medical Devices reported nearly 15% sales growth, with Diabetes Care registering a 28% increase, primarily fueled by FreeStyle Libre. Cardiovascular Devices demonstrated a 10% overall sales growth, highlighted by double-digit Electrophysiology and Structural Heart growth.

Our Report Structure:

⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures

Want unlimited access to our reports? Purchase our $99 annual subscription!